Meeting Banner
Abstract #4406

The Addition of Rituximab to First-Line Chemotherapy for Newly-Diagnosed Diffuse Large B-Cell Lymphoma Does Not Modify the Prediction of Therapy Outcome by Phosphorus MR Spectroscopy

Fernando Arias-Mendoza1, Kristen Zakian2, Geoffrey S. Payne3, Marion Stubbs4, Hamed Mojahed1, Amita Shukla-Dave2, Franklyn Howe5, Harish Poptani6, Mitchell R. Smith<su

1Columbia University Medical Center, New York, NY, United States; 2Memorial Sloan-Kettering Cancer Center, New York, NY, United States; 3Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; 4Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom; 5St. George's Hospital, London, United Kingdom; 6University of Pennsylvania Medical Center, Philadelphia, PA, United States; 7Fox Chase Cancer Center, Philadelphia, PA, United States; 8New York University Medical Center, New York, NY, United States; 9Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands; 10Medical University of South Carolina, Charleston, SC, United States

We have used in vivo phosphorus MR spectroscopy to measure phosphoethanolamine and phosphocholine in tumors of newly diagnosed diffuse large B-cell lymphoma patients prior to the start of first-line chemotherapy and normalized to nucleoside triphosphates (PME/NTP) with the aim to assess whether the correlation of the pretreatment tumor PME/NTP value with treatment outcome differs between those patients treated with first-line chemotherapy alone and those treated with added rituximab.

Abstract PDF E-Poster Video

Keywords

ability absence achieve achieved active added addition alone animal antibody apart approval arias assess assignment basic board brown cancer care cell chase chemotherapy chimeric chop clinical clinically comparing complete corrected correlation correlations curves cutoff decoupled determined diagnosed differs diffuse either endpoints ethical failure free generate hospital human impact in vivo increasing index institute international intracellular jerry john kingdom leach like localized lymphoma many martin measure measures medical memorial metabolism models modify monoclonal months newly normalized nuclear objective outcome outline overall panel patients phosphorus plus predict prediction presence pretreatment prior prognostic protein rank receiving recently relapse related relevance respectively response review risk royal science segregated seven significantly similarly smith south spectroscopy start statistically studied summary surrogate survival therapeutic therapy translate treated treatment treatments tumor tumors twenty undergoing viability wanted whether years